Canada Studies Effects Of Psilocybin For COVID Frontline Healthcare Workers In Phase 2 Clinical Trial
Alberta-based ATMA Journey Centers Inc. has received Health Canada’s approval to move forward with its N500 Phase II psilocybin clinical study investigating the potential relief of COVID-19-associated mental health challenges…